Table of Contents Table of Contents
Previous Page  206 / 398 Next Page
Information
Show Menu
Previous Page 206 / 398 Next Page
Page Background

201

Study of anatomical variance of the zygomaticofacial

foramen and determination of reliable reference points for

surgery

S. Basyuni

∗

, A. Ferro, C. Brassett, V. Santhanam

University of Cambridge, Cambridge, United Kingdom

Background:

Dissection onto the facial aspect of the zygoma is

necessary in several maxillofacial procedures. This carries inher-

ent risk of damage to the vessels exiting the zygomaticofacial

foramen (ZFF) on the facial aspect of the zygoma.

Objectives:

The aimwas to compare ZFF anatomy between ethnic

groups and sexes, and to determine reliable reference points for

surgery.

Methods:

858 zygomatic bones on dry adult skulls were used

in the study. Skulls were selected from nine different geographic

regions for a comparison between ethnic groups, and a compari-

son of anatomy between sexes was completed. Each zygoma was

examined for the number of ZFF, after which a cross-line laser

was used to create two consistent lines from which the ZFF was

measured and mapped.

Findings:

There were significant differences in number and loca-

tion of ZFF between ethnic groups, but not between sexes. Of all

858 sides, 1 ZFF was most commonly identified (49.8%). How-

ever, foramina number ranged from 0 to 4 per zygoma. Despite

this variability over 80% of ZFF bilaterally were found within a

15 mm diameter circle centred at 5 mm anterior to the intersection

of lines discussed above. Moreover, over 90% of ZFF fell beyond

an arc of 5 mm from the orbital margin.

Conclusion:

We present a novel method of identifying a ‘ZFF

zone’ within which the majority of foramina lie. This simple tech-

nique can be of use in directing osteotomy sites, local nerve blocks,

and in preventing iatrogenic damage to the ZFF neurovascular

bundle.

http://dx.doi.org/10.1016/j.ijom.2017.02.684

Osteoinductivity of calcium phosphate ceramics in a sheep

model plus clinical application

R. Bos

∗

, A. van Arnhem, A. van Leeuwen

University Medical Center Groningen, The Netherlands

Background and Objectives:

Ceramics consisting of calcium

phosphates (CaP), seem very promising bone graft substitutes.

They possess osteoinductive properties, without expensive and

hard to obtain osteogenic cells and/or growth factors. The aim of

this study is to investigate the osteoinductivity and biocompatibil-

ity of 6 new ceramics. Also clinical application was tested.

Methods:

Six different CaP ceramics consisting of biphasic cal-

cium phosphate (BCP) and tricalcium phosphate (TCP) were

implanted ectopically in the long dorsal muscles in sheep with

a follow-up of three and nine months. Vital stainings were admin-

istered to monitor bone formation. Light microscopy was used

to evaluate bioactivity, degradation and tissue reaction. Fluores-

cence microscopy and histomorphometry were used to determine

the extent and period of osteoinduction.

Findings:

The BCPs and the TCP scaffold showed osteoinduc-

tive properties, although large inter-animal differences occurred.

Granule size did not seem to influence the bioactivity of the ceram-

ics. The other materials did not present osteoinductive properties.

Regarding the degradation patterns and tissue reactions of the

hosts, all materials were found to be biocompatible.

Conclusion:

The TCP granules were not osteoinductive while the

BCP granules showed high osteoinductive capacities, regardless

the granule size. The osteoinductivity of the TCP scaffold deserves

further research. Besides osteoinductive properties of the BCPs

and TCP scaffold all of our materials proved to be biocompatible.

In the meantime BCP granules have been successfully applied for

reconstruction of large skull defects in children. The technique of

this treatment will be demonstrated.

http://dx.doi.org/10.1016/j.ijom.2017.02.685

A pilot study into prevention of antiresorptive drug-related

osteonecrosis of the jaw in a porcine animal model

G. Brierly

∗

, L. Bray, C. Theodoropoulos, S. Saifzadeh, E. Hsu,

D. Nikolarakos, M. Woodruff, D. Hutmacher

Institute of Health and Biomedical Innovation, Queensland

University of Technology, 60 Musk Avenue, Kelvin Grove,

Brisbane, Australia

Background:

Antiresorptive drug related osteonecrosis of the jaw

(ARONJ) can occur in patients taking bisphosphonates follow-

ing an invasive dental procedure of the bone. At present, there

is no accepted preventative intervention for the condition and its

pathogenesis remains shrouded in mystery.

Objectives:

The objective of this study was to elucidate if the

application of a polyethylene glycol hydrogel with the addition

of platelet-rich plasma (PRP) or recombinant human bone mor-

phogenetic protein-2 (rhBMP-2) to a dentoalveolar socket could

prevent the development of ARONJ in a pig animal model.

Methods:

Three Australian minipigs (

∼

50 kg) were given weekly

IV infusions of zoledronic acid (0.05 mg/kg) over eighteen weeks.

Six weeks after the initial infusion the first premolars and first

molars were removed surgically under general anaesthesia and

defects homogenised to a volume of 785 mm

3

. The defects

were then randomly assigned to a group and the interventions

placed into the sockets. Defects were closed via a mucoperiosteal

advancement flap and 4/0 Vicryl. After euthanasia the extraction

sockets were harvested and processed for laboratory analysis.

Findings:

Visually groups one and eight had necrosis with

exposed bone present. Groups who received rhBMP-2 had the

greatest mucosal closure. Laboratory analysis revealed statisti-

cally significant differences (

P

< 0.05) between the groups that

received rhBMP-2 compared to groups 1 and 8 in bone volume

regenerated, osteoclastic and osteoblastic gene expression, and

angiogenesis.

Conclusions:

The application of a hydrogel or carrier with

rhBMP-2 can stimulate increased angiogenesis and bone turnover

in the local extraction socket environment. Further work is

required to determine the minimum therapeutic dose of rhBMP-2

for ARONJ prevention.

http://dx.doi.org/10.1016/j.ijom.2017.02.686